2023年华东医药股份有限公司中报

Huadong Medicine Co., Ltd. Semi-Annual Report 2023 August 16, 2023 Section I. Important Declaration, Contents and Definitions The Board of Directors, Board of Supervisors, directors, supervisors and senior managers of Huadong Medicine Co., Ltd. (hereinafter referred to as the “Company”) hereby guarantee that the information presented in this semi- annual report is authentic, accurate and complete and free of any false records, misleading statements or material omissions, and shall undertake individual and joint legal liabilities. Lv Liang, the Company’s legal representative and the officer in charge of accounting, and Qiu Renbo, head of the Accounting Department (accounting supervisor) hereby declare and guarantee that the financial statements in this semi-annual report are authentic, accurate and complete. All directors have attended the board meeting to review this semi-annual report. The future plans, development strategies and other forward-looking statements in this semi-annual report shall not be considered as substantial commitment of the Company to investors. Investors and related parties should be fully aware of the risks, and understand the differences between plans, forecasts and commitments. The risks the Company faces in operation include industry policy and product price reduction risk, new drug R&D risk, investment and M&A risk, and exchange rate fluctuation risk. For details, please refer to “X. Potential risks and responses” in “Section III. Management Discussion and Analysis”. Therefore, investors are kindly reminded to pay attention to possible investment risks. The Company does not plan to distribute cash dividends, no bonus share will be issued, and no capital reserve will be converted to increase the share capital. According to “Stock Listing Rules of the Shenzhen Stock Exchange”, if listed companies have both Chinese or other language version of public notice, they should ensure the content of both versions are the same. In the case of discrepancy, the original version in Chinese shall prevail. Contents Section I. Important Declaration, Contents and Definitions ......2 Section II. Company Profile and Key Financial Indicators......9 Section III Discussion andAnalysis of the Management ......13 Section IV. Corporate Governance ......60 Section V Environmental and Social Responsibilities ......63 Section VI. Important Matters......78 Section VII. Share Change and Shareholders......98 Section VIII. Information on Preferred Shares ...... 104 Section IX. Information on Bonds ...... 105 Section X. Financial Report...... 106 Contents of Reference File I. Financial statements signed and stamped by the legal representative, the person in charge of accounting work, and the head of accounting institution (accounting manager). II. The original of all Company’s documents publicly disclosed in the press designated by CSRC during the reporting period and the original of announcements. Definitions Term refers to Definition CSRC refers to China Securities Regulatory Commission SSE refers to Shenzhen Stock Exchange Huadong Medicine/the Company/our refers to Huadong Medicine Co., Ltd. Company CGE refers to China Grand Enterprises, Inc. Huadong Medicine Group refers to Hangzhou Huadong Medicine Group Co., Ltd. Zhongmei Huadong refers to Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Jiangdong Company refers to Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong Co., Ltd. Jiangsu Joyang Laboratories refers to Jiangsu Joyang Laboratories Xi’an Bohua refers to Huadong Medicine (Xi’an) Bohua Pharmaceutical Co., Ltd. Jiuyuan Gene refers to Hangzhou Jiuyuan Gene Engineering Co., Ltd. Doer Biologics refers to Zhejiang Doer Biologics Co., Ltd. Huadong Ningbo Company refers to Huadong Ningbo Medicine Co., Ltd. Chongqing Peg-Bio refers to Chongqing Peg-Bio Biopharm Co., Ltd. Qyuns Therapeutics refers to Qyuns Therapeutics Co., Ltd. Nuoling Bio refers to Nuoling Biomedical technology (Beijing) Co., Ltd. Grand Chanrong refers to Shanghai Grand Industrial and Financial Investment Management Co., Ltd. Hangzhou Gaotou refers to Hangzhou Hi-Tech Venture Capital Management Co., Ltd. Grand Huachuang refers to Beijing Grand Huachuang Investment Co., Ltd. Hangzhou Heda refers to Hangzhou Heda Industrial Fund Investment Co., Ltd. Pharmaceutical Industry Fund/Fuguang Hangzhou Fuguang Hongxin Equity Hongxin refers to Investment Partnership (Limited Partnership) Meihua Hi-Tech refers to Anhui Meihua Hi-Tech Pharmaceutical Co., Ltd. Wuhu Huaren refers to Wuhu Huaren Science and Technology Co., Ltd. Meiqi Health refers to Hubei Meiqi Health Technology Co., Ltd. Angel Group refers to Hubei Angel Biological Group Co., Ltd. CARsgen Therapeutics refers to CARsgen Therapeutics Holdings Limited NAUAnimal Pharmaceutical refers to Jiangsu NAU Animal Pharmaceutical Co., Ltd. Takeda refers to Takeda Pharmaceuticals Company Ltd. Sinclair refers to Sinclair Pharma Limited vTv refers to vTv Therapeutics LLC R2 refers to R2 Technologies, Inc. MediBeacon refers to MediBeacon Inc. ImmunoGen refers to ImmunoGen,Inc. Provention Bio refers to Provention Bio, Inc. RAPT refers to RAPT Therapeutics,Inc. Kylane refers to Kylane Laboratoires SA High Tech refers to High Technology Products, S.L.U. Exscientia refers to Exscientia Ltd. Heidelberg refers to Heidelberg Pharma AG Pharma Kiniksa refers to Kiniksa Pharmaceuticals (UK), Ltd. KiOmed refers to KiOmed Pharma SA Daewon refers to Daewon Pharmaceutical Co., Ltd. AKSO refers to AKSO Biopharmaceutical, Inc. Ashvattha refers to Ashvattha Therapeutic, Inc. SCOHIA refers to SCOHIAPHARMA, Inc. EMAAesthetics refers to EMAAesthetics Limited Julphar refers to Gulf Pharmaceutical Industries PJSC(JULPHAR) Arcutis refers to Arcutis Biotherapeutics, Inc. GMP refers to Good Manufacturing Practice cGMP refers to Current Good Manufacturing Practices GSP refers to Good Supply Practice BE refers to Bioequivalence CDE refers to Center for Drug Evaluation (of Natio